6,938 Shares in Henry Schein, Inc. $HSIC Bought by Foster & Motley Inc.

Foster & Motley Inc. purchased a new stake in Henry Schein, Inc. (NASDAQ:HSIC) in the 2nd quarter, HoldingsChannel reports. The firm purchased 6,938 shares of the company’s stock, valued at approximately $579,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Parallel Advisors LLC boosted its holdings in Henry Schein by 12.7% in the first quarter. Parallel Advisors LLC now owns 1,314 shares of the company’s stock worth $97,000 after purchasing an additional 148 shares in the last quarter. HB Wealth Management LLC boosted its stake in shares of Henry Schein by 1.3% during the 4th quarter. HB Wealth Management LLC now owns 15,034 shares of the company’s stock worth $1,136,000 after acquiring an additional 191 shares in the last quarter. Jain Global LLC increased its holdings in shares of Henry Schein by 2.0% during the 3rd quarter. Jain Global LLC now owns 10,662 shares of the company’s stock valued at $708,000 after acquiring an additional 207 shares during the last quarter. Sanctuary Advisors LLC raised its stake in shares of Henry Schein by 4.5% in the 4th quarter. Sanctuary Advisors LLC now owns 4,856 shares of the company’s stock valued at $367,000 after acquiring an additional 209 shares in the last quarter. Finally, Captrust Financial Advisors lifted its holdings in Henry Schein by 3.6% in the 4th quarter. Captrust Financial Advisors now owns 6,105 shares of the company’s stock worth $461,000 after purchasing an additional 210 shares during the last quarter. Institutional investors own 96.62% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on HSIC shares. UBS Group set a $94.00 price target on Henry Schein and gave the company a “neutral” rating in a report on Wednesday, August 5th. Mizuho decreased their price objective on shares of Henry Schein from $88.00 to $82.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Robert W. Baird set a $97.00 target price on shares of Henry Schein in a research note on Wednesday, May 6th. Morgan Stanley reiterated an “underweight” rating and issued a $64.00 target price (up from $61.00) on shares of Henry Schein in a report on Friday, April 24th. Finally, Citigroup reissued a “buy” rating and set a $112.00 target price (up from $100.00) on shares of Henry Schein in a research report on Wednesday, August 5th. Eight analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $92.93.

Henry Schein Stock Performance

Shares of NASDAQ HSIC opened at $89.29 on Thursday. Henry Schein, Inc. has a 12 month low of $61.94 and a 12 month high of $92.18. The company has a market cap of $9.95 billion, a P/E ratio of 26.03, a P/E/G ratio of 1.70 and a beta of 0.80. The business’s 50 day moving average is $85.43 and its two-hundred day moving average is $79.36. The company has a quick ratio of 0.73, a current ratio of 1.32 and a debt-to-equity ratio of 0.60.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $1.27 earnings per share for the quarter, beating the consensus estimate of $1.24 by $0.03. The company had revenue of $3.46 billion during the quarter, compared to analysts’ expectations of $3.37 billion. Henry Schein had a return on equity of 15.97% and a net margin of 2.96%.Henry Schein’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same period in the prior year, the business earned $1.10 earnings per share. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. On average, equities analysts expect that Henry Schein, Inc. will post 5.35 EPS for the current year.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.